Denali Therapeutics (NASDAQ:DNLI) Shares Up 8.8% - Here's What Happened...
MarketBeat·2d ago
More News
FY2028 Earnings Estimate for DNLI Issued By Leerink Partnrs
Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Analysts at Leerink Partnrs reduced their FY2028 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report released on...
MarketBeat·3d ago
FY2029 EPS Estimates for Denali Therapeutics Cut by Wedbush
Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at Wedbush reduced their FY2029 EPS estimates for shares of Denali Therapeutics in a research note issued to investors on Friday...
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of...
MarketBeat·6d ago
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
Zacks·8d ago
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Zacks·1mo ago
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·2mo ago
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
Zacks·3mo ago
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
Zacks·3mo ago
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.